The latest: Shanghai Henlius Biotech Inc. (2696.HK) said on Thursday its self-developed small cell lung cancer drug Hansizhuang has been granted orphan drug status by the European Commission (EC).

Looking up: The designation, given to drugs to treat relatively rare conditions, will allow the Hansizhuang to enjoy certain policy support in its subsequent development in the EU. Such support includes protocol assistance for clinical studies, access to the centralized authorization procedure and 10 years of market exclusivity after the drug is approved for marketing.

Take Note: Even if Hansizhuang is ultimately approved, it would have to compete with similar drugs already on the market, including Merck & Co.’s (MRK.US) Keytruda, Bristol-Myers Squibb’s (BMY.US) Opdivo and Regeneron Pharmaceuticals’ (REGN.US) Libtayo.

Digging Deeper: Founded in 2010, Henlius is a biopharmaceutical company owned by Fosun Pharma (2196.HK; 600196.SH). The company made a major breakthrough in 2019 when it attained approval for sale of China’s first biosimilar medicine, rituximab, for the treatment of Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Henlius has commercialized five products as of the end of June, leading to significant revenue growth in the past two and a half years. But the company is still not profitable due to high R&D and sales expenses.

Market Reaction: After opening up 5.3% on Friday, Henlius shares moved downward and closed 2.4% lower at HK$12.82 at the midday break. The stock now trades close to its 52-week low.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Switchbot, with DJI Godfather as its non-executive director, is seeking Hong Kong IPO and fanning up market interest

Switchbot taps market frenzy for robotic stocks

The maker of smart home-use robots has filed for a Hong Kong IPO, boasting a key elder of China’s high-tech gadget world as a major shareholder and non-executive director Key…
SICC makes substraits

Sinking SICC looks for lift from Hong Kong IPO

The maker of silicon carbide substrates has been cleared by China’s securities regulator to list in Hong Kong, even as its revenue began to contract in the first quarter Key…
A comeback listing three years after exiting the Hong Kong stock market, what is it about?

Checking out or checking in? Jin Jiang can’t decide

Three years after privatizing its Hong Kong-listed shares, storied hotelier Jin Jiang has rolled out plans to re-list on the city’s stock exchange Key Takeaways: Jin Jiang has applied to…